AstraZeneca beats third-quarter revenue and profit expectations

Core Insights - AstraZeneca exceeded third-quarter earnings expectations, driven by robust sales of key drugs for cancer, heart, and kidney diseases [1] Group 1: Financial Performance - The company reported strong earnings, surpassing market expectations for the third quarter [1] - Sales growth was particularly notable in the oncology, cardiovascular, and renal disease segments [1] Group 2: Market Position - AstraZeneca remains the most valuable listed company in London, reflecting its strong market position and investor confidence [1] - The performance reinforces AstraZeneca's strategic focus on high-demand therapeutic areas [1]